| hepatitis B core‐related antigen (HB crAg): an emerging marker for chronic hepatitis B virus infection LY Mak, DKH Wong, KS Cheung, WK Seto, CL Lai, MF Yuen Alimentary pharmacology & therapeutics 47 (1), 43-54, 2018 | 231 | 2018 |
| Global epidemiology, prevention, and management of hepatocellular carcinoma LY Mak, V Cruz-Ramón, P Chinchilla-López, HA Torres, NK LoConte, ... American Society of Clinical Oncology Educational Book 38, 262-279, 2018 | 224 | 2018 |
| Occult hepatitis B infection and hepatocellular carcinoma: Epidemiology, virology, hepatocarcinogenesis and clinical significance LY Mak, DKH Wong, T Pollicino, G Raimondo, FB Hollinger, MF Yuen Journal of Hepatology 73 (4), 952-964, 2020 | 150 | 2020 |
| Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case‐control study RWH Hui, WK Seto, KS Cheung, LY Mak, KSH Liu, J Fung, DKH Wong, ... Journal of viral hepatitis 25 (1), 97-104, 2018 | 117 | 2018 |
| Association between hepatic steatosis, measured by controlled attenuation parameter, and fibrosis burden in chronic hepatitis B WK Seto, RWH Hui, LY Mak, J Fung, KS Cheung, KSH Liu, DKH Wong, ... Clinical Gastroenterology and Hepatology 16 (4), 575-583. e2, 2018 | 115 | 2018 |
| Diverse effects of hepatic steatosis on fibrosis progression and functional cure in virologically quiescent chronic hepatitis B LY Mak, RWH Hui, J Fung, F Liu, DKH Wong, KS Cheung, MF Yuen, ... Journal of hepatology 73 (4), 800-806, 2020 | 111 | 2020 |
| Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels YF Lam, WK Seto, D Wong, KS Cheung, J Fung, LY Mak, J Yuen, ... Clinical and translational gastroenterology 8 (10), e125, 2017 | 108 | 2017 |
| Role of serum HBV RNA and hepatitis B surface antigen levels in identifying Asian patients with chronic hepatitis B suitable for entecavir cessation WK Seto, KSH Liu, LY Mak, G Cloherty, DKH Wong, J Gersch, YF Lam, ... Gut 70 (4), 775-783, 2021 | 85 | 2021 |
| HBV RNA profiles in patients with chronic hepatitis B under different disease phases and antiviral therapy LY Mak, G Cloherty, DKH Wong, J Gersch, WK Seto, J Fung, MF Yuen Hepatology 73 (6), 2167-2179, 2021 | 70 | 2021 |
| Use of HBsAg quantification in the natural history and treatment of chronic hepatitis B LY Mak, WK Seto, J Fung, MF Yuen Hepatology International 14, 35-46, 2020 | 63 | 2020 |
| Nidogen 1‐enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1 X Mao, SK Tey, CLS Yeung, EML Kwong, YME Fung, CYS Chung, ... Advanced Science 7 (21), 2002157, 2020 | 61 | 2020 |
| Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD-a systematic review and meta-analysis A Tang, CH Ng, PH Phang, KE Chan, YH Chin, CE Fu, RW Zeng, J Xiao, ... Clinical Gastroenterology and Hepatology 21 (7), 1750-1760. e12, 2023 | 57 | 2023 |
| Long‐term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e‐antigen seroclearance J Fung, KS Cheung, DKH Wong, LY Mak, WP To, WK Seto, CL Lai, ... Hepatology 68 (2), 462-472, 2018 | 57 | 2018 |
| Epidemiology and natural history of Wilson’s disease in the Chinese: a territory-based study in Hong Kong between 2000 and 2016 KS Cheung, WK Seto, J Fung, LY Mak, CL Lai, MF Yuen World Journal of Gastroenterology 23 (43), 7716, 2017 | 55 | 2017 |
| The effect of diabetes and prediabetes on the prevalence, complications and mortality in nonalcoholic fatty liver disease CH Ng, KE Chan, YH Chin, RW Zeng, PC Tsai, WH Lim, DJH Tan, ... Clinical and Molecular Hepatology 28 (3), 565, 2022 | 50 | 2022 |
| Letter regarding “A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement” LY Mak, MF Yuen, WK Seto Journal of hepatology 73 (6), 1573-1574, 2020 | 50 | 2020 |
| Hepatocellular carcinoma: recent advances and emerging medical therapies KL Ko, LY Mak, KS Cheung, MF Yuen F1000Research 9, 2020 | 50 | 2020 |
| RNA interference as a novel treatment strategy for chronic hepatitis B infection RWH Hui, LY Mak, WK Seto, MF Yuen Clinical and molecular hepatology 28 (3), 408, 2022 | 46 | 2022 |
| Fibrosis evolution in chronic hepatitis B e antigen‐negative patients across a 10‐year interval LY Mak, WK Seto, RWH Hui, J Fung, DKH Wong, CL Lai, MF Yuen Journal of viral hepatitis 26 (7), 818-827, 2019 | 46 | 2019 |
| Novel developments of hepatitis B: treatment goals, agents and monitoring tools LY Mak, WK Seto, J Fung, MF Yuen Expert review of clinical pharmacology 12 (2), 109-120, 2019 | 46 | 2019 |
Man-Fung YuenProfessor, Department of Medicine, The University of Hong Kong在 hkucc.hku.hk 的电子邮件经过验证
